logo

BIOA

BioAge Labs·NASDAQ
--
--(--)
--
--(--)
3.28 / 10
Netural

BIOA's fundamental score is 3.28/10, reflecting weak fundamentals. Key positives include a high inventory turnover ratio (47.88) and solid interest coverage (15.51), but these are offset by subpar asset and revenue valuation metrics. The company's total operating revenue grew 78.62% YoY, yet profitability and market valuation remain concerns, supporting a prudent investment stance.

Fundamental(3.28)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.90
Score1/3
Weight9.26%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.73%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.23%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight21.50%
1M Return8.99%
PB-ROE
Value-0.36
Score3/3
Weight30.93%
1M Return13.65%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.32%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.20%
1M Return0.10%
Asset-MV
Value-0.51
Score1/3
Weight22.13%
1M Return8.68%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.83%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight20.64%
1M Return8.80%
Is BIOA undervalued or overvalued?
  • BIOA scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -18.20% ROE, 0.00% net margin, -10.95 P/E ratio, 3.12 P/B ratio, and 139.69% earnings growth, these metrics solidify its Netural investment rating.